Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)Terminated
NCT05014139Phase 1Updated Nov 20, 2025
Sponsor: Astellas Pharma Global Development, Inc.
Urinary Bladder Neoplasms · Carcinoma in Situ · Carcinoma Transitional Cell · Non-muscle Invasive Bladder Cancer
United States, Canada, France, Germany, Spain +1 more
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in IndiaCompleted
NCT06086353N/AUpdated Nov 20, 2025
Sponsor: Pfizer
Transthyretin Amyloid Cardiomyopathy
India
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Completed
NCT06321523N/AUpdated Nov 20, 2025
Sponsor: Pfizer
Transthyretin Amyloid Cardiomyopathy
South Korea
A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid ArthritisTerminated
NCT05891600N/AUpdated Nov 20, 2025
Sponsor: Pfizer
Rheumatoid Arthritis
Colombia
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19Active Not Recruiting
NCT06923137N/AUpdated Nov 19, 2025
Sponsor: Pfizer
COVID-19 SARS-CoV-2 Infection · COVID-19 · COVID-19 Infection · Coronavirus Disease 2019 (COVID-19)
United States
STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)Active Not Recruiting
NCT07122661N/AUpdated Nov 19, 2025
Sponsor: Pfizer
Respiratory Syncytial Virus (RSV) · Respiratory Syncytial Virus · Lower Respiratory Tract Disease · Respiratory Tract Diseases
Australia
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.Available
NCT06025227N/AUpdated Nov 18, 2025
Sponsor: Pfizer
Colitis, Ulcerative
ATGAM General InvestigationActive Not Recruiting
NCT06039020N/AUpdated Nov 18, 2025
Sponsor: Pfizer
Aplastic Anemia
Japan
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCompleted
NCT03079011Phase 3Updated Nov 18, 2025
Sponsor: UNICANCER
Metastatic Breast Cancer
France
Korea Post Marketing Surveillance (PMS) Study of Talzenna®Not Yet Recruiting
NCT04982848N/AUpdated Nov 18, 2025
Sponsor: Pfizer
Breast Neoplasms
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)Completed
NCT05399485Phase 3Updated Nov 18, 2025
Sponsor: Pfizer
Migraine
Japan
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)Available
NCT05522556N/AUpdated Nov 18, 2025
Sponsor: Pfizer
Alopecia Areata
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031Terminated
NCT03573882Phase 3Updated Nov 18, 2025
Sponsor: Pfizer
Sickle Cell Disease
United States, Canada, Egypt, France, Italy +6 more
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.Completed
NCT06086340N/AUpdated Nov 18, 2025
Sponsor: Pfizer
Breast Cancer
United States
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.Active Not Recruiting
NCT06733337N/AUpdated Nov 17, 2025
Sponsor: Pfizer
Prostate Cancer
Japan
A Study to Learn More About Tukysa Once it is Out in the Korean MarketNot Yet Recruiting
NCT06873191N/AUpdated Nov 17, 2025
Sponsor: Pfizer
HER2-positive Locally Advanced Unresectable · Metastatic Breast Cancer
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast CancerActive Not Recruiting
NCT06735742N/AUpdated Nov 17, 2025
Sponsor: Pfizer
Breast Cancer
Japan
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy AdultsCompleted
NCT07172321Phase 1Updated Nov 17, 2025
Sponsor: Pfizer
Atopic Dermatitis
United States
A Study of PF-06873600 in People With CancerTerminated
NCT03519178Phase 1, Phase 2Updated Nov 14, 2025
Sponsor: Pfizer
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
United States, Bulgaria, Canada, Japan, Russia +1 more
Open-Label Extension of VoxelotorTerminated
NCT04188509Phase 3Updated Nov 13, 2025
Sponsor: Pfizer
Sickle Cell Disease
United States, Egypt, Lebanon, Nigeria, United Kingdom
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)Terminated
NCT05935748Phase 2Updated Nov 12, 2025
Sponsor: NiKang Therapeutics, Inc.
ccRCC · Clear Cell Renal Cell Carcinoma · Kidney Cancer · Kidney Neoplasms
United States
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.Completed
NCT04955626Phase 3Updated Nov 10, 2025
Sponsor: BioNTech SE
SARS-CoV-2 Infection · COVID-19
United States, Brazil, Germany, Israel, South Africa
A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) InfectionTerminated
NCT06079320Phase 2, Phase 3Updated Nov 10, 2025
Sponsor: Pfizer
Respiratory Syncytial Virus Infection
United States, China, India, Japan
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerActive Not Recruiting
NCT03672773Phase 2Updated Nov 10, 2025
Sponsor: Jonsson Comprehensive Cancer Center
Recurrent Extensive Stage Small Cell Lung Carcinoma · Refractory Extensive Stage Small Cell Lung Carcinoma
United States
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)Completed
NCT03587116Phase 3Updated Nov 6, 2025
Sponsor: Pfizer
Hemophilia B · Hemophilia A
United States, Australia, Belgium, Brazil, Canada +13 more

Previous page Next page